Bromelain

Authors:Prof. Dr. med. Peter Altmeyer, Prof. Dr. med. Martina Bacharach-Buhles

All authors of this article

Last updated on: 02.03.2023

Dieser Artikel auf Deutsch

Synonym(s)

Bromelin; Broomelaine (INN); CAS No.: 9001-00-7; Extranase; Pineapple; Trauma Nose

Requires free registration (medical professionals only)

Please login to access all articles, images, and functions.

Our content is available exclusively to medical professionals. If you have already registered, please login. If you haven't, you can register for free (medical professionals only).


Requires free registration (medical professionals only)

Please complete your registration to access all articles and images.

To gain access, you must complete your registration. You either haven't confirmed your e-mail address or we still need proof that you are a member of the medical profession.

Finish your registration now

DefinitionThis section has been translated automatically.

The term "bromelain" is a (single) name for 2 enzymes from the protease family. These are sulfhydryl-containing cysteine proteases (glycoproteins) obtained from the fruit stalks of Ananas cosmosus (Fam Bromeliaceae). Bromelain is sparingly soluble in water and sparingly soluble in ethanol and ether. The enzyme develops its optimal proteolytic activity in the range of pH 4 -10.

Also called bromelain are the extracts obtained from pineapple, which, in addition to cysteine proteases, contain papain-like endopeptidases, several protease inhibitors, a peroxidase, acid phosphatase, and organically bound calcium .

Commission E-monography: acute swelling states, postoperative, post-traumatic, especially facial area, paranasal sinuses.

Empirical medicine: sports injuries, traumatic edema, thrombophlebitis, rheumatic diseases, digestive problems in pancreatic insufficiency.

EffectsThis section has been translated automatically.

Bromelain and the enzymes exogenously supplied with it are partially absorbed as intact proteins via the gastrointestinal tract. In humans, measurable concentrations of bromelain-specific proteases can be detected by quantitative determination procedures proportional to the administered dose (Castell 1997). The highest bromelain blood concentrations are found approximately 1 hour after oral administration. In the blood, bromelain is rapidly complexed to alpha2-macroglobulin (AMG) while maintaining specific enzyme activity (Kelly GS -1996; Maurer HR 2001). The bromelain effects are detectable as early as 20-60 minutes after oral application and subside after about 24 hours.

Bromelain effects are described as anti-edematous, anti-inflammatory, antithrombotic and fibrinolytic (Cooreman WM-1976, Leipner J et al.2001, Taussig SJ 1998). The large number of preclinical, pharmacological, animal and cell experimental findings provide a secure scientifically founded basis for further randomized and controlled clinical intervention studies.

Field of application/useThis section has been translated automatically.

The monopreparation bromelain was monographed in 1994 by Commission E with suggestions for dosage and indications.

  • Systemic use: Medicinally, bromelaiin preparations are preferably used as adjunctive therapy in diseases with inflammatory, post-traumatic and -operative soft tissue oedema. They are therefore also of medical interest, especially in sports medicine and traumatology. In the treatment of sports injuries with post-traumatic swelling and oedema conditions, bromelad administration represents an alternative to therapy with non-steroidal anti-inflammatory drugs (NSAIDs).
  • postoperative swelling for 4-5 days

Furthermore:

  • Substitution therapy for digestive disorders
  • Technically, the drug is used in the pre-treatment of meat (softening effect).

Undesirable effectsThis section has been translated automatically.

In addition to allergic reactions, occasional gastrointestinal symptoms such as diarrhea and stomach discomfort have been described as temporary side effects.

Prolongation of bleeding time, reduction of platelet aggregation.

Discontinue before planned operations!

Standard concentrationThis section has been translated automatically.

Initial dose 4x40mg/p.o./day; maintenance dose 4x20mg/p.o./day.

Bromelain Pos 1 Kps contains 500 F.I.P. units, corresponding to 56.25-95 mg bromelain

ContraindicationThis section has been translated automatically.

Taking anticoagulants. Possible hypersensitivity to bromelain. Pregnancy, lactation (no clinical information available). Planned surgery

InteractionsThis section has been translated automatically.

Possible increase of the bleeding tendency with simultaneous therapy with anticoagulants and platelet aggregation inhibitors.

Trade namesThis section has been translated automatically.

Monopreparations:

  • Bromelain-POS®, Traumanase®, Traumanase forte®, Wobenzym mono® (D), Bromelain-R.A.N®.

Combination preparations:

  • Innovazym® , Phlogenzym®, Wobenzym®, DOG TG.

Note(s)This section has been translated automatically.

Bromelain is used medicinally both as a mono-preparation and as a combination preparation.

LiteratureThis section has been translated automatically.

  1. Castell JV et al (1997) Intestinal absorption of undegraded proteins in men: presence of bromelain in plasma after oral intake. Am J Physiol 273 139-146.
  2. Chandler DS et al (1998) Bromelain protects piglets from diarrhea caused by oral challenge with K88 positive enterotoxigenic Escherichia coli. Gut 43: 196-202.
  3. Cooreman WM etg al (1976) Bromelain, biochemical and pharmacological properties. Pharm Acta Helv 51: 73-97.
  4. Kelly GS (1996) Bromelain: A literature review and discussion of its therapeutic applications. Alt Med Rev 1: 243-257.
  5. Leipner J et al (2001) Therapy with proteolytic enzymes in rheumatic disorders. Bio Drugs 15: 779-789.
  6. Maurer A (1996) On the bioavailability of bromelain contained in two different formulations after multiple oral dosage. Eur J Clin Pharmacol 50: 549.
  7. Maurer HR (2001) Bromelain: biochemistry, pharmacology and medical use. Cell Mol Life Sci 58: 1234-1245.
  8. Pavan R et al (2012) Properties and therapeutic application of bromelain: a review. Biotechnol Res Int:976203.
  9. Rathnavelu V et al. (2016) Potential role of
  10. bromelain in clinical and therapeutic applications. Biomed Rep 5:283-288.
  11. Taussig SJ et al (1988) Bromelain, the enzyme complex of pineapple (Ananas comosus) and its clinical application. An update. J Ethnopharmacol 22:191-203.
  12. Wenigmann M. (2017) Phytotherapy medicinal drugs, phytopharmaceuticals, application. Urban & Fischer, p. 90

Authors

Last updated on: 02.03.2023